KRAS and non-small cell lung carcinoma: Moreover, in NSCLC cell lines and tumors from a mouse model of Kras-driven lung cancer, p65BTK levels were highest in samples with a mutation in KRAS or in the RAS/MAPK pathway and – accordingly to what previously shown in CRC – p65BTK expression was dependent on the RAS/MAPK pathway, indicating that p65BTK might be an actionable target in a significant number of lung tumors.